718.15
2.96 (0.41%)
| Previous Close | 715.19 |
| Open | 716.07 |
| Volume | 553,987 |
| Avg. Volume (3M) | 817,548 |
| Market Cap | 78,917,509,120 |
| Price / Earnings (TTM) | 17.77 |
| Price / Earnings (Forward) | 15.53 |
| Price / Sales | 5.84 |
| Price / Book | 2.63 |
| 52 Weeks Range | |
| Earnings Date | 31 Jan 2025 - 4 Feb 2025 |
| Profit Margin | 33.61% |
| Operating Margin (TTM) | 33.43% |
| Diluted EPS (TTM) | 40.40 |
| Quarterly Revenue Growth (YOY) | 10.60% |
| Quarterly Earnings Growth (YOY) | 33.00% |
| Total Debt/Equity (MRQ) | 9.22% |
| Current Ratio (MRQ) | 5.28 |
| Operating Cash Flow (TTM) | 4.25 B |
| Levered Free Cash Flow (TTM) | 2.25 B |
| Return on Assets (TTM) | 7.41% |
| Return on Equity (TTM) | 17.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Regeneron Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | 4.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.0 |
| Average | 0.90 |
|
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 1.57% |
| % Held by Institutions | 90.66% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,215.00 (RBC Capital, 69.19%) | Buy |
| Median | 1,067.50 (48.65%) | |
| Low | 165.00 (Canaccord Genuity, -77.02%) | Hold |
| Average | 989.88 (37.84%) | |
| Total | 12 Buy, 3 Hold, 1 Sell | |
| Avg. Price @ Call | 810.43 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 14 Jan 2025 | 795.00 (10.70%) | Hold | 696.88 |
| 14 Nov 2024 | 895.00 (24.63%) | Hold | 782.51 | |
| Wells Fargo | 10 Jan 2025 | 900.00 (25.32%) | Buy | 696.88 |
| 22 Oct 2024 | 1,050.00 (46.21%) | Buy | 962.34 | |
| Truist Securities | 08 Jan 2025 | 1,004.00 (39.80%) | Buy | 733.59 |
| 01 Nov 2024 | 1,126.00 (56.79%) | Buy | 843.60 | |
| Bernstein | 07 Jan 2025 | 1,070.00 (48.99%) | Buy | 730.30 |
| Canaccord Genuity | 17 Dec 2024 | 165.00 (-77.02%) | Hold | 740.01 |
| B of A Securities | 10 Dec 2024 | 565.00 (-21.33%) | Sell | 778.50 |
| Wolfe Research | 15 Nov 2024 | 1,150.00 (60.13%) | Buy | 756.81 |
| Oppenheimer | 06 Nov 2024 | 1,000.00 (39.25%) | Buy | 816.65 |
| BMO Capital | 01 Nov 2024 | 1,190.00 (65.70%) | Buy | 843.60 |
| Barclays | 01 Nov 2024 | 1,065.00 (48.30%) | Buy | 843.60 |
| 23 Oct 2024 | 1,080.00 (50.39%) | Buy | 941.39 | |
| Morgan Stanley | 01 Nov 2024 | 1,184.00 (64.87%) | Buy | 843.60 |
| Piper Sandler | 01 Nov 2024 | 1,195.00 (66.40%) | Buy | 843.60 |
| RBC Capital | 01 Nov 2024 | 1,215.00 (69.18%) | Buy | 843.60 |
| 25 Oct 2024 | 1,260.00 (75.45%) | Buy | 933.02 | |
| Evercore ISI Group | 24 Oct 2024 | 1,175.00 (63.61%) | Buy | 928.90 |
| JP Morgan | 24 Oct 2024 | 1,150.00 (60.13%) | Buy | 928.90 |
| Cantor Fitzgerald | 23 Oct 2024 | 1,015.00 (41.34%) | Hold | 941.39 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SING GEORGE L | 715.19 | 712.33 | -1,782 | -1,268,897 |
| Aggregate Net Quantity | -1,782 | |||
| Aggregate Net Value ($) | -1,268,897 | |||
| Aggregate Avg. Buy ($) | 715.19 | |||
| Aggregate Avg. Sell ($) | 712.33 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SING GEORGE L | Director | 02 Jan 2025 | Acquired (+) | 166 | 715.19 | 118,722 |
| SING GEORGE L | Director | 31 Dec 2024 | Disposed (-) | 1,948 | 712.33 | 1,387,619 |
| SING GEORGE L | Director | 31 Dec 2024 | Option execute | 3,338 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |